Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX vs Irinotecan/Docetaxel in ERCC1-stratified Esophageal/Gastric Cancer
NCT01498289Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2012
- Primary completion
- Mar 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, docetaxel in esophageal cancer, gastric cancer (GC), adenocarcinoma of the gastroesophageal junction, sponsored by SWOG Cancer Research Network. Started Feb 2012; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabdocetaxel
03
Conditions
esophageal cancergastric cancer (GC)adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT01498289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498289.